Ex-vivo investigation of radiofrequency ablation in pancreatic adenocarcinoma after neoadjuvant chemotherapy.
Gemma RossiMaria Chiara PetroneMarco Schiavo LenaLuca AlbarelloDiego PalumboSabrina Gloria Giulia TestoniLivia ArchibugiMatteo TacelliPiera ZaccariGiuseppe VanellaLaura ApadulaStefano CrippaGiulio BelfioriMichele ReniMassimo FalconiClaudio DoglioniFrancesco De CobelliAndrew J HealeyGabriele CapursoPaolo Giorgio ArcidiaconoPublished in: DEN open (2022)
RFA causes histologically evident damage with coagulative necrosis of a few millimeters in 80% of ex-vivo PDAC samples after chemotherapy and no clinical or pre-operative CT features can predict efficacy. Power settings do not correlate with the histological ablation area. These results are of relevance when employing RFA in vivo and planning clinical trials on its role in PDAC patients.
Keyphrases
- radiofrequency ablation
- neoadjuvant chemotherapy
- locally advanced
- clinical trial
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- lymph node
- computed tomography
- peritoneal dialysis
- sentinel lymph node
- oxidative stress
- randomized controlled trial
- rectal cancer
- radiation therapy
- magnetic resonance imaging
- magnetic resonance
- atrial fibrillation
- open label